AcuFocus is pleased to announce they received approval from the Korean
Food and Drug Administration (KFDA) for the KAMRA™ inlay, making this
revolutionary treatment option for near vision loss available to the
Korean population. The majority of people experience loss of near
vision, or presbyopia, as they age. The KAMRA corneal inlay is designed
to only permit focused light rays to enter the eye, allowing patients to
see near and intermediate objects more clearly without glasses. Patients
who have undergone this procedure are once again seeing details such as
mobile devices, labels, and time on a wristwatch with ease.
As a novel technology, the KAMRA inlay went through a very rigorous
approval process. The KFDA required extensive data on clinical results,
safety, device design and biocompatibility. "We are extremely thrilled
to be able to offer this advanced vision correction technology in
Korea," said Ed Peterson, AcuFocus President and Chief Executive
Officer. "The approval from the KFDA is a testament to the excellent
global results achieved with the device."